These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12952815)

  • 1. And the winner of the vaccine is..
    Mackay B
    CMAJ; 2003 Sep; 169(5):460. PubMed ID: 12952815
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financing immunizations in the United States.
    Hinman AR; Orenstein WA; Rodewald L
    Clin Infect Dis; 2004 May; 38(10):1440-6. PubMed ID: 15156483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
    Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
    Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the dangers of pediatric pneumococcal disease with a new vaccine.
    Toth S; Davis RH; Donnelly RE; Leger MM; Muma RD; Taft JM
    JAAPA; 2001 Feb; 14(2):58-9. PubMed ID: 11523192
    [No Abstract]   [Full Text] [Related]  

  • 7. Financing immunization of adults in the United States.
    Orenstein WA; Mootrey GT; Pazol K; Hinman AR
    Clin Pharmacol Ther; 2007 Dec; 82(6):764-8. PubMed ID: 17971821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [National economic consequences of vaccines].
    Bergman A; Persson U
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1680-4. PubMed ID: 18590011
    [No Abstract]   [Full Text] [Related]  

  • 9. [Vaccination--value for money?].
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary care physician perspectives on reimbursement for childhood immunizations.
    Freed GL; Cowan AE; Clark SJ
    Pediatrics; 2008 Dec; 122(6):1319-24. PubMed ID: 19047252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).
    Isaacman DJ; Fletcher MA; Fritzell B; Ciuryla V; Schranz J
    Vaccine; 2007 Mar; 25(13):2420-7. PubMed ID: 17049677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood vaccine finance and safety issues.
    Giffin R; Stratton K; Chalk R
    Health Aff (Millwood); 2004; 23(5):98-111. PubMed ID: 15371374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of pneumococcal conjugate vaccination in Finland.
    Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
    Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Government financing for health and specific national budget lines: the case of vaccines and immunization.
    Lydon P; Beyai PL; Chaudhri I; Cakmak N; Satoulou A; Dumolard L
    Vaccine; 2008 Dec; 26(51):6727-34. PubMed ID: 18625279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise and challenge of adolescent immunization.
    National Vaccine Advisory Committee
    Am J Prev Med; 2008 Aug; 35(2):152-7. PubMed ID: 18617084
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants.
    Esposito S; Pugni L; Bosis S; Proto A; Cesati L; Bianchi C; Cimino C; Mosca F; Principi N
    Vaccine; 2005 Feb; 23(14):1703-8. PubMed ID: 15705475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimbursement for Prevnar: a modern-day version of Hercules and the Hydra.
    Freed GL; Davis MM; Andreae MC; Bass S; Weinblatt H
    Pediatrics; 2002 Aug; 110(2 Pt 1):399-400. PubMed ID: 12165597
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity.
    Hennessy TW; Singleton RJ; Bulkow LR; Bruden DL; Hurlburt DA; Parks D; Moore M; Parkinson AJ; Schuchat A; Butler JC
    Vaccine; 2005 Dec; 23(48-49):5464-73. PubMed ID: 16188350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heptavalent pneumococcal conjugate vaccine: current and future impact.
    Hsu KK; Pelton SI
    Expert Rev Vaccines; 2003 Oct; 2(5):619-31. PubMed ID: 14711324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.